EF Hutton Maintains Buy on Immunic, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Immunic (NASDAQ:IMUX) and maintained a price target of $17.
September 18, 2024 | 6:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Immunic, maintaining a price target of $17. This suggests confidence in the company's future performance.
The reaffirmation of a Buy rating and a $17 price target by EF Hutton indicates a positive outlook on Immunic's stock, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100